Screener
Ultragenyx Pharmaceutical RARE Royalty — Accounts Receivable Net
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Ultragenyx Pharmaceutical in its filing.
Tagged under the XBRL concept us-gaap:AccountsReceivableNet.
The source filing: Ultragenyx Pharmaceutical’s 10-Q, filed August 5, 2026.
- Filed
- Aug 4, 2026, 8:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-333233
The Company had accounts receivable from KKC in the amount of $94 million and $98 million from royalties, other receivables of $1 million and $1 million recorded in other current assets, and accrued liabilities of $16 million and $12 million from amounts owed for transfer price and royalties as well as commercial and development activity reimbursements, as of June 30, 2026 and December 31, 2025, respectively.
Item 1. Financial Statements
FAQ
- What is Ultragenyx Pharmaceutical's royalty — accounts receivable net?
- Ultragenyx Pharmaceutical (RARE) reported royalty — accounts receivable net of $94M in Q2 2026.
- What does royalty — accounts receivable net mean?
- This metric measures the outstanding balance of royalty payments owed to the company by licensees for products sold, net of any allowances for doubtful accounts. It represents the short-term credit extended to partners as part of the royalty collection cycle. Tracking this balance provides insight into the company's ability to efficiently convert royalty-based contractual earnings into actual cash flow.
Ask your AI about Ultragenyx Pharmaceutical's royalty — accounts receivable net.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude